Performance Assessment of a Rapid Molecular Respiratory Syncytial Virus Point-of-Care Test: A Prospective Community Study in Older Adults

DSpace/Manakin Repository

Performance Assessment of a Rapid Molecular Respiratory Syncytial Virus Point-of-Care Test: A Prospective Community Study in Older Adults
 
Respiratory Syncytial Virus Consortium in Europe (RESCEU) Investigators
(2022) The Journal of infectious diseases, volume 226, issue Supplement_1, pp. S63 - S70
(Article)
Abstract
Background. Respiratory syncytial virus (RSV) causes a substantial burden in older adults. Viral load in RSV-infected adults is generally lower compared to young children, which could result in suboptimal sensitivity of RSV diagnostics. Although the Xpert® Xpress Flu/RSV assay has been used in routine clinical care, its sensitivity to diagnose ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Aged, Child, Child, Preschool, Humans, Influenza A virus/genetics, Influenza B virus/genetics, Influenza, Human/diagnosis, Molecular Diagnostic Techniques/methods, Nasopharynx, Point-of-Care Testing, Prospective Studies, Respiratory Syncytial Virus Infections/diagnosis, Respiratory Syncytial Virus, Human/genetics, Sensitivity and Specificity, diagnosis, molecular, older adults, point-of-care test, respiratory syncytial virus, Journal Article, Research Support, Non-U.S. Gov't
DOI: https://doi.org/10.1093/infdis/jiab600
ISSN: 0022-1899
Publisher: Oxford University Press
Note: Funding Information: Potential conflicts of interest. N. A. reports grants and nonfinancial support from European Union’s Horizon 2020 Research and Innovation Programme and EFPIA, during the conduct of the study. O. G. reports personal fees from GSK, outside the submitted work. C. B. reports grants from the European Union, during the conduct of the study; and personal fees from Roche, grants and personal fees from Janssen Pharmaceuticals, and grants from the National Institute of Health Care Research, outside the submitted work. S. C. reports grants and nonfinancial support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA, during the conduct of the study. L. J. B. has regular interaction with pharmaceutical and other industrial partners, but has not received personal fees or other personal benefits. He is also the founding chairman of the ReSViNET Foundation. University Medical Centre Utrecht has received major funding (>€100,000 per industrial partner) for investigator-initiated studies from AbbVie, MedImmune, Janssen, the Bill & Melinda Gates Foundation, Nutricia (Danone), and MeMed Diagnostics; major cash or in-kind funding as part of the public-private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen, AstraZeneca, Pfizer, and Sanofi; major funding by Julius Clinical for participating in the INFORM study sponsored by MedImmune; minor funding for participation in trials by Regeneron and Janssen from 2015 to 2017 (total annual estimate <€20,000); and minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer, and Janssen (total annual estimate <€20,000). All other authors report no potential conflicts of interest. Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.
(Peer reviewed)